NICE previously paused the publication of final draft guidance recommending evinacumab for the treatment of homozygous familial hypercholesterolaemia in people aged 12 and older [ID2704]. NICE has now decided to withdraw the final draft guidance for evinacumab. This is because there is some uncertainty about the dose of lomitapide (the comparator for evinacumab in adults) used in the cost effectiveness analysis of evinacumab, and this raises some uncertainty about the cost effectiveness of evinacumab.
Commencing on 8 April 2024, NICE will hold a 28-day stakeholder engagement in which stakeholders are requested to provide information on the dose and efficacy of lomitapide in clinical practice. NICE will then hold a committee meeting to consider the dose of lomitapide and its impact on the cost effectiveness of evinacumab.